Kirby Institute Seminar Series presents
Theme Leader (Immunity & Inflammatory Diseases), Garvan Institute of Medical Research
Stuart Tangye is Leader of Immunity & Inflammation Research Theme at the Garvan Institute of Medical Research (Sydney, Australia), and Professor in the Faculty Medicine, UNSW Sydney. His research interests focus on the biology of human lymphocytes in health and disease, and elucidating mechanisms whereby defects in signalling, activation and function underlie the development and clinical features of immunodeficiencies. This is achieved by studying lymphocyte biology in patients with diseases resulting from inborn errors of immunity in key regulators of immune responses. His lab has made significant contributions to elucidating how these mutations result in the clinical features associated with human primary immunodeficiencies, including understanding the requirements for generating memory B cells, Tfh cells and Th17 cells, and defects in immune responses to EBV infection.
He has published ~185 peer-reviewed articles, been funded by the NHMRC, Cancer Council NSW, NIH, Jeffrey Modell Foundation, XLP Research Trust, Association for International Cancer Research, and the Job Research Foundation. He also holds major positions on the editorial boards of J Exp Med, J Immunol, J Clin Immunol and Front Immunol, and is currently the chair of the IUIS Expert Committee of Inborn Errors of Immunity. His contributions to research have been recognized by being awarded the Gottschalk Medal from the Australian Academy of Sciences (2011), the Faculty of Science UTS Alumni Award for Excellence (2013), a Fulbright Scholarship from the USA:Australian Fulbright Commission (2015), and the Presidential Award from the Clinical Immunology Society (USA, 2019).
When he is not at work, he enjoys surfing, cycling, swimming and being a Dad to his three beautiful children, and partner to his amazing wife Gill!
Unravelling the genetic cause of immune dysregulatory conditions not only provides a molecular explanation for the condition, but can also influence patient management and treatments, and open up opportunities for novel research endeavours at the interface of basic and clinical immunology. The experience of the Clinical Immunogenomics Research Consortium of Australasia (CIRCA) into the field of monogenic immune diseases will be presented and discussed.